Investors

BioAdvance works closely with entrepreneurs to build strong companies in the mid-Atlantic region which are focused on improving human health.

BioAdvance is a $50 million early stage life sciences fund, working with entrepreneurs in the mid-Atlantic region to build strong companies that have the potential to improve human health. Since making its first investments in 2003, BioAdvance has committed $35.7 million in funding to 80 organizations developing over 75 products in the diagnostics, therapeutic, medtech, research tools and digital health sectors. BioAdvance portfolio companies have leveraged $2.65 billion in subsequent capital, including proceeds from twelve acquisitions. Eleven products have received FDA approval.